Nicholas Piramal India (NPIL), a pharmaceutical company, operates in the therapeutic segments of anti-bacterials, cardiovasculars, anti-diabetics, nutritionals, central nervous system and gastro-intestinals. In addition, it has a presence in the OTC segment through its various joint ventures and alliances. Nicholas Piramal`s primary brands Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint account for 67 per cent of the company`s turnover, whereas its secondary brands such as Paraxin, Flagyl and Omnatax account for 24 per cent of its turnover. The secondary brands, however, are the company`s cash cows. NPIL has inked joint ventures with Allergan (eye-care), Ambalal Sarabhai (distribution of ethical products), Boots (OTC products), Shree Dhootapapeshwar (ayurvedic medicines), Laporte (food additives), Bupa (Wellspring Hospital), Charak Pharmaceuticals (ayurvedic) and Solumiks Pharma (ayurvedic). It also has access to newly patented products coming out of the research pipeline of F.Hoffmann-La Roche and Boehringer Mannheim. The company has four subsidiaries namely Gujarat Glass Ltd, Ceylon Glass Co. Ltd, Drs.Tribedi & Roy Diagnostic Laboratories and Dr Phadke Pathalogy Laboratory & Infertility Centre. In December 2000, NPIL acquired 60 per cent stake in Rhone Poulenc India. The company`s manufacturing actrivities are well supported by active research and development, a phenomenon which has shown a healthy growth in the past five years. It has set up an R&D facility called the `Quest Institute of Life Sciences` in Mumbai that focusses on process development.
Piramal Healthcare Share Market Live Price & Charts
Nicholas Piramal India (NPIL), a pharmaceutical company, operates in the therapeutic segments of anti-bacterials, cardiovasculars, anti-diabetics, nutritionals, central nervous system and gastro-intestinals. In addition, it has a presence in the OTC segment through its various joint ventures and alliances. Nicholas Piramal`s primary brands Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint account for 67 per cent of the company`s turnover, whereas its secondary brands such as Paraxin, Flagyl and Omnatax account for 24 per cent of its turnover. The secondary brands, however, are the company`s cash cows. NPIL has inked joint ventures with Allergan (eye-care), Ambalal Sarabhai (distribution of ethical products), Boots (OTC products), Shree Dhootapapeshwar (ayurvedic medicines), Laporte (food additives), Bupa (Wellspring Hospital), Charak Pharmaceuticals (ayurvedic) and Solumiks Pharma (ayurvedic). It also has access to newly patented products coming out of the research pipeline of F.Hoffmann-La Roche and Boehringer Mannheim. The company has four subsidiaries namely Gujarat Glass Ltd, Ceylon Glass Co. Ltd, Drs.Tribedi & Roy Diagnostic Laboratories and Dr Phadke Pathalogy Laboratory & Infertility Centre. In December 2000, NPIL acquired 60 per cent stake in Rhone Poulenc India. The company`s manufacturing actrivities are well supported by active research and development, a phenomenon which has shown a healthy growth in the past five years. It has set up an R&D facility called the `Quest Institute of Life Sciences` in Mumbai that focusses on process development.
